ACRIVON THERAPEUTICS INC
ACRVNASDAQTrading Snapshot
- Day Range
- $1.71 – $1.73
- 52-Week Range
- $1.21 – $3.56
- Volume
- $2.71B
- Avg Volume
- $2.81B
- Shares Outstanding
- 42.8M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.00
- Dividend Yield
- 0.00%
Why Investors Own ACRV
- ✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 66% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ACRIVON THERAPEUTICS INC
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC)
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly regimen (3 days on/4 days
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic index Early clinical responses, including partial responses (PRs) across multiple AP3-predicted tumor types, underscore how AP3-guided drug design translates into differentiated anti-tumor activity WATERTOWN, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon T
Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei Shi, Ph.D., Director